Table 1 Demographics, renal BILAG scores and medications for LN patients
From: Mesangial cells are key contributors to the fibrotic damage seen in the lupus nephritis glomerulus
Demographics | Active LN (n = 6) | Inactive LN (n = 6) | Healthy Controls (n = 6) |
|---|---|---|---|
Age (years) (median [range]) | 15.53 [12.18–16.58] | 14.55 [11.03–17.79] | 14.9 [12.12–16.6] |
Age at diagnosis (years) (median [range]) | 12.8 [6.28–13.29] | 10.46 [6.28–16.88] | – |
Females (%) | 100 (6) | 100 (6) | 100 (6) |
Nationality % (n) | |||
White British | 16.6 (1) | 33.3 (2) | 100 (6) |
Chinese | 16.6 (1) | 16.6 (1) | 0 |
Somali | 33.3 (2) | 33.3 (2) | 0 |
African | 16.6 (1) | 16.6 (1) | 0 |
Indian | 16.6 (1) | 0 | 0 |
Renal BILAG domains | |||
Renal Hypertension (%) n | 16.6 (1) | 0 | – |
Urine ACR (mg/dL) (median [range]) | 239.3 [0.7–592.4] | 7.5 [0.8–8.8] | |
Renal Creatinine (mg/dL) (median [range]) | 45 [37–62] | 51 [30–61] | |
Estimated GFR (mL/min/1.73m2) (median [range]) | 138 [99.8–158.1] | 121.5 [99.1–181.9] | |
Medications (n) | |||
Hydroxychloroquine | 4 | 3 | – |
Azathioprine | 0 | 3 | |
Mycophenolate mofetil | 6 | 3 | |
Prednisolone | 5 | 5 | |
Methotrexate (oral) | 0 | 0 | |
Rituximab | 1 | 0 | |
Cyclophosphamide | 1 | 0 | |